SAR443579 在至少 12 岁患有复发性或难治性急性髓性白血病 (R/R AML)、B 细胞急性淋巴细胞白血病 (B-ALL) 或高风险的男性和女性参与者中进行的首次人体研究骨髓增生异常 (HR-MDS)
SAR443579 作为单一药物在复发或难治性急性髓性白血病 (R/R AML)、B 细胞急性淋巴细胞白血病 (B-ALL) 患者中静脉输注的开放标签、首次人体剂量递增研究) 或高风险骨髓增生异常 (HR-MDS)
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
-
Tianjin、中国、300020
- Investigational Site Number : 1560001
-
Zhengzhou、中国、450008
- Investigational Site Number : 1560003
-
-
-
-
-
Marseille、法国、13009
- Investigational Site Number :2500002
-
Paris、法国、75010
- Investigational Site Number :2500001
-
Paris、法国、75019
- Investigational Site Number : 2500004
-
Villejuif、法国、94800
- Investigational Site Number :2500003
-
-
-
-
Victoria
-
Melbourne、Victoria、澳大利亚、3000
- Investigational Site Number :0360002
-
Melbourne、Victoria、澳大利亚、3004
- Investigational Site Number :0360001
-
-
-
-
California
-
Duarte、California、美国、91010
- City of Hope-Site Number:8400002
-
-
Georgia
-
Atlanta、Georgia、美国、30303
- Emory University School of Medicine- Grady Campus- Site Number : 8400006
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Beth Israel Deaconess Medical Center-Site Number:8400004
-
-
New York
-
New York、New York、美国、10021
- Weill Cornell Medical College-Site Number:8400003
-
The Bronx、New York、美国、10461
- Montefiore Hutchinson Campus- Site Number : 8400012
-
-
Ohio
-
Columbus、Ohio、美国、43210
- The Ohio State University- Site Number : 8400009
-
-
Oregon
-
Portland、Oregon、美国、97239
- Oregon Health and Science University-Site Number:8400011
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- The Children's Hospital of Philadelphia- Site Number : 8400013
-
-
Texas
-
Houston、Texas、美国、77030
- MD Anderson Cancer Center-Site Number:8400001
-
-
Washington
-
Seattle、Washington、美国、98105
- Seattle Children's Hospital- Site Number : 8400014
-
-
-
-
-
Amsterdam、荷兰、1081 HV
- Investigational Site Number :5280002
-
Groningen、荷兰、9713 GZ
- Investigational Site Number :5280003
-
Nijmegen、荷兰、6525 GA
- Investigational Site Number : 5280005
-
Rotterdam、荷兰、3015 CE
- Investigational Site Number :5280001
-
Utrecht、荷兰、3584 CS
- Investigational Site Number :5280004
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 在试验参与者或法定监护人签署知情同意书时,参与者必须年满 12 岁。
仅限升级部分的参与者:
- 根据世界卫生组织 (WHO) 分类,确诊为原发性或继发性 AML [除急性早幼粒细胞白血病 (APL) 以外的任何亚型]。 AML 患者必须满足以下标准之一,a)、b) 或 c),并且仅限于那些没有可用(或不合格)治疗且具有已知临床益处的患者。
a) 原发性诱导失败 (PIF) AML,定义为以下 i 或 ii 之一难治的疾病。
i) 每个机构的密集入职尝试。 诱导尝试包括高剂量和/或标准剂量阿糖胞苷±蒽环类药物/蒽二酮±抗代谢物,有或没有生长因子或含有靶向治疗的方案。
示例包括但不限于:
- 一个周期的高剂量阿糖胞苷(HiDAC)含方案
- 脂质体阿糖胞苷和柔红霉素一个周期
两个周期的标准剂量含阿糖胞苷的方案 ii) 对于 75 岁或以上的成年人,或患有无法使用强化诱导化疗的合并症的成年人; PIF 被定义为对以下强度较低的方案之一(1 或 2)难治的 AML:
- 4个周期的低甲基化剂(HMA)或
2 个周期的 HMA + venetoclax b) 早期复发 (ER) AML,定义为复发的 AML,最近一次治疗后 CR 持续时间 < 6 个月 c) 第一次或多次复发的白血病
- 确诊为分化簇 123 (CD123) + HR-MDS,修订后的国际预后评分系统 (IPSS-R) 风险类别为中等或更高,并且仅限于那些没有可用(或不合格)已知临床治疗的患者益处。
- 不符合诱导治疗的条件并且已完成 ≥ 2 个周期的以下任何一种:低甲基化剂(例如,5 阿扎胞苷或地西他滨)和/或维奈托克、化疗或靶向药物。
不符合自体干细胞移植 (ASCT) 条件且已完成≥1 个疗程的诱导治疗。
- 确诊为 CD123 + B-ALL,无髓外病变,无可用(或不合格)治疗且已知临床获益。
仅限扩展部分的参与者:
- 对于队列 A 中的参与者:符合 AML 患者纳入标准的参与者,这些患者既往诱导治疗原发性难治性 (PIF) 或在先前诱导治疗初始缓解后 6 个月或更短时间内出现 ER。
- 对于队列 B 中的参与者:符合晚期复发 (LR) AML 患者纳入标准的参与者,这些患者在先前诱导治疗的初始缓解后发生超过 6 个月。
- 体重>40公斤。 -- 体重 >40 公斤。 - - -
排除标准:
- 东部肿瘤协作组 (ECOG) 体能状态 >2(≥18 岁)。 卡尔诺夫斯基量表(16-17岁)
- 需要或需要治疗的活动性或慢性自身免疫病史。
- 需要积极治疗的第二原发性恶性肿瘤。 允许辅助激素治疗。
- 通过细胞学或病理学证明在入组时有活动性中枢神经系统白血病的证据。
- 已知的获得性免疫缺陷综合征(艾滋病相关疾病)或需要抗逆转录病毒治疗的人类免疫缺陷病毒(HIV)疾病,或患有活动性乙型或丙型肝炎感染,或严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)感染。 有 SARS-CoV-2 感染史的参与者必须在入组前至少 1 个月完成临床康复。 - 先前使用抗 CD123 药物治疗。
- 只有在停止免疫抑制至少 4 周并且没有移植物抗宿主病 (GVHD) 证据的情况下,才可以包括先前复发超过 3 个月的 HSCT。
- 在首次研究性药物产品 (IMP) 给药时接受皮质类固醇作为合并用药,皮质类固醇剂量 >10 mg/天的口服泼尼松或等效药物,
- 先前使用细胞疗法进行治疗,例如嵌合抗原受体 T 细胞 (CAR-T) 或嵌合抗原受体 NK 细胞 (CAR-NK)。
- 与其他研究药物同时治疗。
- 放射治疗,即使是姑息性的,也可能不会在研究期间进行。
- 仅在剂量递增部分的 DLT 观察期间预防性使用造血生长因子(例如粒细胞集落刺激因子 (G-CSF)、粒细胞巨噬细胞集落刺激因子 (GM-CSF)、促红细胞生成素)。 - 由于监管或法律秩序而被安置在机构中的个人;被合法收容的囚犯或参与者。
- 孕妇和哺乳期妇女。
- 实体器官移植史,包括角膜移植。
- 筛选时平均 QTc(使用 Fridericia 校正计算)>470 毫秒 (msec)。
上述信息并非旨在包含与潜在参与临床试验相关的所有考虑因素。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SAR443579
剂量递增:SAR443579 以递增的剂量水平静脉内给药。 剂量扩展:SAR443579 以根据剂量递增确定的推荐剂量和时间表静脉内给药。 |
输液用粉末;通过静脉输液
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
大体时间:Cycle 1 Day 1 up to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.
|
The DLT was defined as any of the following events during Cycle 1 (first 28 days) using NCI CTCAE v5.0 or ASTCT criteria, whether related or not to the study treatment in the absence of clear evidence to the contrary, and if not related to disease progression.
Hematologic DLTs included hematologic toxicities, bone marrow hypocellularity, decreased neutrophils lasting, febrile neutropenia, decreased platelet count lasting, anemia (all Grade 4), and Grade 3 thrombocytopenia.
Non-hematologic DLTs included any Grade >=3 toxicities except alopecia, Grade 3 fatigue, asthenia, fever, anorexia, constipation, nausea, vomiting, diarrhea, total parenteral nutrition, hospitalization related events, infection, bleeding, Grade 3 infusion related reaction and laboratory abnormalities, Grade 3 or 4 tumor lysis syndrome and isolated electrolyte abnormalities.
Also, DLTs were any treatment related toxicity causing >2 week delay in recovery to baseline/Grade <=1 or requiring dose reduction.
|
Cycle 1 Day 1 up to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.
|
|
Dose Escalation (Cohort C): Number of Participants With Dose Limiting Toxicities
大体时间:Cycle 1 Day 1 to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.
|
The DLT was defined as any of the following events during Cycle 1 (first 28 days) using NCI CTCAE v5.0 or ASTCT criteria, whether related or not to the study treatment in the absence of clear evidence to the contrary, and if not related to disease progression.
Hematologic DLTs included hematologic toxicities, bone marrow hypocellularity, decreased neutrophils lasting, febrile neutropenia, decreased platelet count lasting, anemia (all Grade 4), and Grade 3 thrombocytopenia.
Non-hematologic DLTs included any Grade >=3 toxicities except alopecia, Grade 3 fatigue, asthenia, fever, anorexia, constipation, nausea, vomiting, diarrhea, total parenteral nutrition, hospitalization related events, infection, bleeding, Grade 3 infusion related reaction and laboratory abnormalities, Grade 3 or 4 tumor lysis syndrome and isolated electrolyte abnormalities.
Also, DLTs were any treatment related toxicity causing >2 week delay in recovery to baseline/Grade <=1 or requiring dose reduction.
|
Cycle 1 Day 1 to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.
|
|
Dose Expansion (Cohorts A1, A2 and D): Composite Complete Remission (CRc) Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
The CRc rate was defined as the percentage of participants who had a response of complete remission (CR), CR with partial hematologic recovery (CRh) or CR with incomplete hematologic recovery (CRi) according to modified AML International Working Group (IWG) 2003 response criteria.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohort B): Overall Response Rate (ORR)
大体时间:Tumors were planned to assess on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first.
|
The ORR was defined as the percentage of participants who had a response of CR, CR equivalent, partial remission (PR), CR with limited count recovery (CRL), CRh or hematologic improvement (HI) according to IWG 2023 myelodysplastic syndrome (MDS) response criteria.
|
Tumors were planned to assess on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dose Expansion (Cohorts A1, A2, B and D): Recommended Dose for Expansion (RDE)
大体时间:Cycle 1 Day 1 up to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.
|
The RDE of SAR443579 was determined based on the occurrence of DLTs in Cycle 1.
|
Cycle 1 Day 1 up to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.
|
|
Dose Escalation and Dose Expansion (Cohort A1): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
大体时间:From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 117.3 weeks for dose escalation (adult), 12 weeks for dose escalation (pediatric) and 20.9 for dose expansion (Cohort A1).
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
An SAE was defined as any AE that: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect; or was an important medical event.
The TEAEs were defined as events that were newly reported or reported to worsen in severity after the first administration of study treatment up to 30 days after the last administration of study treatment.
|
From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 117.3 weeks for dose escalation (adult), 12 weeks for dose escalation (pediatric) and 20.9 for dose expansion (Cohort A1).
|
|
Dose Escalation and Dose Expansion (Cohort A1): Minimum Plasma Concentration (Ctrough) of SAR443579
大体时间:At Days 1, 4, 8, 11, 15, 22, and 28 of Cycle 1
|
Blood samples are collected just before treatment administration during repeated dosing to determine the Ctrough of SAR443579.
|
At Days 1, 4, 8, 11, 15, 22, and 28 of Cycle 1
|
|
Dose Escalation and Dose Expansion (Cohort A1): Percentage of Participants With Anti-drug Antibodies (ADA) Against SAR443579
大体时间:From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 117.3 weeks for dose escalation (adult), 12 weeks for dose escalation (pediatric) and 20.9 for dose expansion (Cohort A1).
|
Plasma samples were collected to assess the antibodies to SAR443579.
Treatment-emergent ADA was defined as a participant with at least 1 treatment-induced or treatment-boosted ADA-positive sample at any time during the treatment or follow-up observation period.
Non-treatment emergent ADA was defined as participant without any treatment-induced, treatment-boosted ADA-positive or ADA-inconclusive sample during the treatment or follow-up observation period.
|
From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 117.3 weeks for dose escalation (adult), 12 weeks for dose escalation (pediatric) and 20.9 for dose expansion (Cohort A1).
|
|
Dose Escalation and Dose Expansion (Cohort C): Composite Complete Remission Rate Assessed by Acute Myeloid Leukemia 2003 Modified International Working Group Response Criteria and National Comprehensive Cancer Network (NCCN)
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapse, unacceptable AE, discontinuation or death. Maximum treatment duration: 117.3 weeks (adults) and 12 weeks (pediatrics) in dose escalation phase.
|
The CRc rate was defined as the percentage of participants who had a response of CR, CRh or CRi according to modified AML IWG 2003 response criteria.
For Dose Expansion (Cohort C), the CRc rate was planned to be assessed according to NCCN.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapse, unacceptable AE, discontinuation or death. Maximum treatment duration: 117.3 weeks (adults) and 12 weeks (pediatrics) in dose escalation phase.
|
|
Dose Escalation and Dose Expansion (Cohort C): Alternative Complete Remission Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapse, unacceptable AE, discontinuation or death. Maximum treatment duration: 117.3 weeks (adults) and 12 weeks (pediatrics) in dose escalation phase.
|
Alternative CR rate was defined as percentage of participants with CR and CRh according to modified AML IWG 2003 response criteria.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapse, unacceptable AE, discontinuation or death. Maximum treatment duration: 117.3 weeks (adults) and 12 weeks (pediatrics) in dose escalation phase.
|
|
Dose Escalation and Dose Expansion (Cohort C): Overall Response Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapse, unacceptable AE, discontinuation or death. Maximum treatment duration: 117.3 weeks (adults) and 12 weeks (pediatrics) in dose escalation phase.
|
Overall response rate was defined as percentage of participants who had a CR or CRi or CRh or PR or morphological leukemia-free state (MLFS) according to modified AML IWG 2003 response criteria.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapse, unacceptable AE, discontinuation or death. Maximum treatment duration: 117.3 weeks (adults) and 12 weeks (pediatrics) in dose escalation phase.
|
|
Dose Expansion (Cohorts A1, A2 and D): Overall Response Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
Overall response rate was defined as percentage of participants who had a CR or CRi or CRh or PR or MLFS according to modified AML IWG 2003 response criteria.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2 and D): Duration of Composite Complete Remission Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
Duration of CRc was defined as the time interval from first documented evidence of CRc (CR, CRh or CRi) until disease relapse (DR) or death due to any cause, whichever comes first.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2, B and D): Duration of Overall Response Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
Duration of overall response rate was defined as the time from the first documented evidence of CR or CRi or CRh or PR or MLFS until DR or death due to any cause, whichever comes first.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2, B and D): Alternative Complete Remission Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
Alternative CR rate was defined as percentage of participants with CR and CRh according to modified AML IWG 2003 response criteria.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2, B and D): Duration of Alternative Complete Remission Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
Duration of alternative CR was defined as the time from the first documented evidence of CR or CRh until DR or death due to any cause, whichever comes first.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2, B and D): Event-Free Survival (EFS)
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
The EFS was defined as the time interval from the first day of treatment assignment to the date of earliest evidence of relapse, treatment failure, or death.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2, B and D): Overall Survival (OS)
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
The OS was defined as time interval from the first day of treatment assignment to death from any cause.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2, B and D): Rate of Hematopoietic Stem Cell Transplantation (HSCT)
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
The HSCT rate was defined as the percentage of participants who had received HSCT immediately following study treatment administration but prior to subsequent therapy for treatment of AML.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2, B and D): Time to Treatment Failure (TTF)
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
The TTF was defined as the time from first day of treatment assignment to discontinuation for any reason excluding remission, example, relapsed disease, refractory disease, unacceptable AE, participant preference or death.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohorts A1, A2 and D): Transfusion Independence (TI) Rate
大体时间:Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
The TI rate was defined differently for participants who were transfusion dependency (TD) at baseline and participants who were transfusion independency (TI) at baseline.
For subgroup of participants with TD at baseline, the TI rate was defined as the percentage of participants who convert from baseline TD to TI during on treatment period; For subgroup of participants with TI at baseline, the TI rate was defined as the percentage of participants who remain TI during 56-day post baseline period during treatment.
|
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.
|
|
Dose Expansion (Cohort B): Progression Free Survival (PFS)
大体时间:Tumors were planned to assess on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first.
|
The PFS was defined as the time interval from the first day of treatment assignment to the date of disease progression, relapse from CR (or CR equivalent), PR, CRL, CRh, or HI, death due to any cause, whichever comes first.
|
Tumors were planned to assess on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first.
|
合作者和调查者
赞助
调查人员
- 研究主任:Clinical Sciences & Operations、Sanofi
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TCD17197
- U1111-1266-7399 (注册表标识符:ICTRP)
- 2021-004287-98 (EudraCT编号)
- 2023-508357-58 (注册表标识符:CTIS)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.